A practical framework and online tool for mutational signature analyses show intertissue variation and driver dependencies
Open accessAbstract
Mutational signatures are patterns of mutations that arise during tumorigenesis. We present an enhanced, practical framework for mutational signature analyses. Applying these methods to 3,107 whole-genome-sequenced (WGS) primary cancers of 21 organs reveals known signatures and nine previously undescribed rearrangement signatures. We highlight interorgan variability of signatures and present a way of visualizing that diversity, reinforcing our findings in an independent analysis of 3,096 WGS metastatic cancers. Signatures with a high level of genomic instability are dependent on TP53 dysregulation. We illustrate how uncertainty in mutational signature identification and assignment to samples affects tumor classification, reinforcing that using multiple orthogonal mutational signature data is not only beneficial, but is also essential for accurate tumor stratification. Finally, we present a reference web-based tool for cancer and experimentally generated mutational signatures, called Signal (https://signal.mutationalsignatures.com), that also supports performing mutational signature analyses. Degasperi et al. introduce a practical framework and Signal, an online tool, to analyze mutational signatures. They find evidence of tissue-specific variability in mutational signatures, which may impact tumor classification and clinical application.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Application of HRDetect in primary tumors revealed that the prevalence of HRD extends beyond BRCA1/2-deficient breast cancer tumors and occurs at varying frequencies in different cancer types.
“Application of this tool in primary tumors revealed that the prevalence of HRD extends beyond BRCA1/2-deficient breast cancer tumors, and occurs at varying frequencies in different cancer types10.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [10]
Predictions of CHORD and HRDetect on the PCAWG dataset were concordant for 1506/1526 (99%) samples.
“In addition, the predictions of CHORD and HRDetect on the PCAWG dataset10 were concordant for the vast majority of samples (1506/1526; 99%) (Supplementary Fig. 10).”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [10]
The Methods (Datasets; page unavailable) identify the PCAWG cohort, and the Results (Homologous recombination deficiency across 21 organs; page unavailable) discuss HRDetect predictions. Searches for CHORD and for the 1506/1526 concordance figure found no passage comparing CHORD with HRDetect, so our copy does not verify the claimed 99% agreement. (LLM, conf=0.73)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 33 · Cited by 304
Research works printed but not linked: 3
- [8]Lee DD Seung HS Advances in neural information processing systems 556 562
- [32]Wagstaff K Proceedings of the Eighteenth International Conference on Machine Learning Morgan Kaufmann Publishers Inc 2001 577 584
- [33]Martello S Toth P North-Holland Mathematics Studies Elsevier 1987 132 259 282
- Authors
- Degasperi, A., Amarante, T. D., Czarnecki, J., Shooter, S., Zou, X., Glodzik, D., Morganella, S., Nanda, A. S., Badja, C., Koh, G., Momen, S. E., Georgakopoulos-Soares, I., Dias, J. M. L., Young, J., Memari, Y., Davies, H., & Nik-Zainal, S.
- Affiliations
- University of Cambridge (GB)
- Wellcome Sanger Institute (GB)
- Addenbrooke's Hospital (GB)
- ORCID
- Venue
- Nature Cancer
- Published
- 2020-02-17
- Volume
- 1
- Issue
- 2
- Pages
- 249-263
- ISSN
- 2662-1347 (ISSN-L)
- PMC
- PMC7048622
- OpenAlex
- W3006132030
- Semantic Scholar
- bf93d47317a49646d6b8994e9568fbed44556064
- Cited by
- 304
- References
- 33
- Citations by year
- 2026: 34 · 2025: 37 · 2024: 51 · 2023: 84 · 2022: 46 · 2021: 38 · 2020: 14
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-06-17)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Cancer Research UK (C60100/A23433, C60100/A23916, C60100/A25274)
- Wellcome Trust (WT100126/B/13/Z)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- mutational signatures, tumor classification, tumor stratification
- MeSH terms
- Humans, Mutation, Neoplasms, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review